Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Kidney cancer has lagged other tumor types in adopting circulating tumor DNA (ctDNA) analysis because it sheds very little DNA into the blood. Only recently have diagnostic assays become sensitive enough to reliably detect it, finally unlocking its potential as a clinical biomarker for guiding adjuvant therapy.
Related Insights
True early cancer detection involves finding microscopic tumor DNA in blood samples. This can identify cancer years before it's visible on an MRI, creating an opportunity for a patient's own immune system to potentially eliminate it before it ever becomes a clinical disease.
Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.
Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.
Despite significant academic interest, the KIM1 plasma biomarker is far from clinical implementation. Key hurdles include the lack of a commercially available, standardized assay and prospectively validated cutoff points. It remains an experimental tool with high variability and unproven utility.
The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.
Experts suggest urinary tumor DNA (utDNA) may better reflect local disease in the bladder, while circulating tumor DNA (ctDNA) indicates systemic disease. Using both tests in parallel could provide a more complete picture, with dual-negative results potentially becoming a key criterion for safely pursuing bladder-sparing approaches.
Tumor-informed ctDNA assays, which require a tissue sample, are highly sensitive and well-suited for the adjuvant setting where tissue is available and time is less critical. In the metastatic setting, logistical challenges and the need for faster results make this approach less practical.
Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) offer complementary information. Used together, they provide superior risk stratification. Patients negative on both tests have a >70% chance of a complete pathological response, while those positive on both have only a ~5% chance, demonstrating clear additive value.
Hematologic cancers often have a single, common genetic marker per disease, enabling MRD detection with simple PCR for decades. Solid tumors are genetically diverse, lacking a universal marker. This required developing personalized, multi-probe assays like Signatera to track unique mutations, explaining the field's more recent progress.
